Technology from computing powerhouse Nvidia is already hard at work inside companies at the convergence of technology and biology, including the supercomputer driving Recursion Pharmaceutical’s drug ...

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...

Recursion Pharmaceuticals' stock jumped after the FDA announced plans to replace the use of animals in drug testing. Recursion is a leader in AI-powered drug discovery and development. It remains to ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the best medical AI stocks to buy now. On March 31, Recursion moved to ...

Small-cap biotech companies can deliver outsized returns over the long run if they develop breakthrough medicines that go on to generate massive sales. However, some of these smaller drugmakers aren't ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research collaboration may initiate up to seven oncology ...

Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...